BLA 022523 · Vivus INC
Pancreaze
Pancrelipase (Amylase, Lipase, Protease) · Oral
Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Apr 12, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
n/a
n/a Phase 3, n/a recruiting
FAERS reports
678
365 serious, 49 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 6, 2025.
PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. PANCREAZE ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. ( 1 )
Mechanism: Pancreatic enzyme products contain a mixture of lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas.
Therapeutic areas: Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 12, 2010 Original approval · Type 7 - Drug Already Marketed without Approved NDA ReviewPediatric Medical ReviewPediatric Statistical Review
6 products under this application
- PANCREAZE · PANCRELIPASE (AMYLASE 149,900USP UNITS; LIPASE 37,000USP UNITS; PROTEASE) 97,300USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- PANCREAZE · PANCRELIPASE (AMYLASE 98,400USP UNITS; LIPASE 16,800USP UNITS; PROTEASE) 56,800USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- PANCREAZE · PANCRELIPASE (AMYLASE 24,600USP UNITS; LIPASE 4,200USP UNITS; PROTEASE) 14,200USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- PANCREAZE · PANCRELIPASE (AMYLASE 15,200USP UNITS; LIPASE 2,600USP UNITS; PROTEASE) 8,800USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- PANCREAZE · PANCRELIPASE (AMYLASE 83,900USP UNITS; LIPASE 21,000USP UNITS; PROTEASE) 54,700USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- PANCREAZE · PANCRELIPASE (AMYLASE 61,500USP UNITS; LIPASE 10,500USP UNITS; PROTEASE) 35,500USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pancrelipase (Amylase" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea63
- drug dose omission36
- death29
- abdominal pain upper28
- infective pulmonary exacerbation of cystic fibrosis27
- nausea27
- pneumonia27
- pain25
- cystic fibrosis23
- drug ineffective23
- vomiting22
- abdominal pain20
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 16 |
| 2011 | 45 |
| 2012 | 33 |
| 2013 | 12 |
| 2014 | 10 |
| 2015 | 83 |
| 2016 | 57 |
| 2017 | 53 |
| 2018 | 45 |
| 2019 | 38 |
| 2020 | 69 |
| 2021 | 45 |
| 2022 | 33 |
| 2023 | 40 |
| 2024 | 44 |
| 2025 | 29 |
| 2026 | 26 |
Recalls
1 FDA enforcement reports for this application.
Jun 23, 2023 · Class III · Ongoing
Failed Stability Specifications
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pancreaze (Lipase/Protease/Amylase)
2024 spending
$12.4M
Beneficiaries
2,375
7,942 claims
Per beneficiary
$5,235
$6.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,241,895 |
| 2021 | $6,839,270 |
| 2022 | $8,180,968 |
| 2023 | $10,310,701 |
| 2024 | $12,433,009 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis.
Trapnell BC, Strausbaugh SD, Woo MS, et al. · J Cyst Fibros 2011 · Randomized Controlled Trial
Sponsor: Vivus INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.